Compare MLYS & USNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLYS | USNA |
|---|---|---|
| Founded | 2019 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 317.0M |
| IPO Year | 2023 | 1996 |
| Metric | MLYS | USNA |
|---|---|---|
| Price | $26.84 | $17.53 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $48.67 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 128.3K |
| Earning Date | 03-12-2026 | 04-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.43 | N/A |
| EPS | N/A | ★ 0.58 |
| Revenue | N/A | ★ $1,060,902,000.00 |
| Revenue This Year | N/A | $3.89 |
| Revenue Next Year | N/A | $6.22 |
| P/E Ratio | ★ N/A | $30.48 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.44 | $16.76 |
| 52 Week High | $47.65 | $38.32 |
| Indicator | MLYS | USNA |
|---|---|---|
| Relative Strength Index (RSI) | 53.26 | 43.14 |
| Support Level | $26.85 | $16.80 |
| Resistance Level | $30.53 | $18.11 |
| Average True Range (ATR) | 1.51 | 0.56 |
| MACD | 0.24 | 0.13 |
| Stochastic Oscillator | 71.75 | 59.63 |
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
Usana Health Sciences Inc is a direct selling and direct-to-consumer nutrition, personal health and wellness company. It developed and manufactured science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness. The company has two reportable segments: direct selling and Hiya direct-to-consumer. The direct selling segment develops and manufactures high quality, science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness in various geographic markets that are distributed through the direct selling channel. The Hiya direct-to-consumer segment is a provider of children's health and wellness products in the U.S. Key revenue is generated from Direct selling segment.